Does Taking GLP-1 Drugs Before Bariatric Surgery Affect Long-Term Outcomes?

Preoperative GLP-1 therapy before bariatric surgery was evaluated for its impact on weight loss and complications over three years.

Poljo, Adisa et al.·Obesity surgery·2025·low-moderateObservational
RPEP-13074Observationallow-moderate2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
low-moderate
Sample
N=N=215
Participants
Adults who underwent RYGB or sleeve gastrectomy (2015-2021)

What This Study Found

Propensity-matched analysis evaluated whether preoperative GLP-1 use affects bariatric surgery outcomes over three years.

Key Numbers

N=215 (54 GLP-1, 161 non-GLP-1); pre-op TWL 3.7%; 12-month TWL: 29.8% vs 28.1%; 24-month: 28.9% vs 27.2%; 36-month: 26.9% vs 25.4%.

How They Did This

Retrospective cohort with propensity score matching (1:1) comparing preoperative GLP-1 users vs. non-users after RYGB or SG.

Why This Research Matters

As more patients try GLP-1 drugs before surgery, knowing whether prior medication use helps or hinders surgical outcomes is critical.

The Bigger Picture

This addresses the evolving treatment sequencing question — whether GLP-1 drugs complement or compete with bariatric surgery.

What This Study Doesn't Tell Us

Retrospective design with potential unmeasured confounders despite propensity matching. Excluded revision surgeries and postoperative GLP-1 use.

Questions This Raises

  • ?Should GLP-1 therapy be routinely offered before bariatric surgery?
  • ?Does preoperative weight loss via GLP-1 drugs reduce surgical complications?

Trust & Context

Key Stat:
3-year follow-up Long-term outcomes tracked after bariatric surgery in patients with and without preoperative GLP-1 use
Evidence Grade:
Retrospective cohort with propensity matching — good methodology for observational research but cannot replace a randomized trial.
Study Age:
Published in 2025, addressing a rapidly evolving clinical question in obesity treatment sequencing.
Original Title:
Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.
Published In:
Obesity surgery, 35(9), 3847-3857 (2025)
Database ID:
RPEP-13074

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Should I try GLP-1 drugs before bariatric surgery?

This study evaluated that exact question. Some patients use GLP-1 drugs first, then pursue surgery — the impact on long-term outcomes was analyzed.

Why do patients switch from GLP-1 drugs to surgery?

Reasons include insufficient weight loss with medication alone, desire for more durable results, or difficulty maintaining medication access.

Read More on RethinkPeptides

Cite This Study

RPEP-13074·https://rethinkpeptides.com/research/RPEP-13074

APA

Poljo, Adisa; Reichl, Jakob J; Bürgi, Simon; Dirnberger, Amanda S; Schneider, Romano; Klasen, Jennifer M; Billeter, Adrian T; Müller, Beat P; Peterli, Ralph; Kraljević, Marko. (2025). Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.. Obesity surgery, 35(9), 3847-3857. https://doi.org/10.1007/s11695-025-08136-5

MLA

Poljo, Adisa, et al. "Surgical Outcomes in Patients with Preoperative GLP-1 Therapy: A Retrospective Analysis.." Obesity surgery, 2025. https://doi.org/10.1007/s11695-025-08136-5

RethinkPeptides

RethinkPeptides Research Database. "Surgical Outcomes in Patients with Preoperative GLP-1 Therap..." RPEP-13074. Retrieved from https://rethinkpeptides.com/research/poljo-2025-surgical-outcomes-in-patients

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.